Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BOSTON SCIENTIFIC CORP Director's Dealing 2018

Feb 23, 2018

29821_dirs_2018-02-23_954fe737-165f-42a4-96d6-8dfe660d1218.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2018-02-21

Reporting Person: Pierce David A (SVP,Pres Urology,Pelvic Health)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-02-21 Common Stock S 16286.0000 $27.0000 Disposed 24201.0000 Direct
2018-02-22 Common Stock M 2607.0000 $0.0000 Acquired 26808.0000 Direct
2018-02-22 Common Stock F 1159.0000 $26.4800 Disposed 25649.0000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-02-22 Deferred Stock Units $ M 2607.0000 Disposed 2021-02-22 Common Stock (2607.0000) Direct

Footnotes

F1: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2: Represents the weighted average sale price. These shares were sold in multiple transactions at $27.00 and $27.005. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.